These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 23153584

  • 1. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells.
    Lu Y, Feng F, Yang Y, Gao X, Cui J, Zhang C, Zhang F, Xu Z, Qv J, Wang C, Zeng Z, Zhu Y, Yang Y.
    Cell Signal; 2013 Feb; 25(2):479-89. PubMed ID: 23153584
    [Abstract] [Full Text] [Related]

  • 2. LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell.
    Yang Q, Feng F, Zhang F, Wang C, Lu Y, Gao X, Zhu Y, Yang Y.
    Cell Signal; 2013 Dec; 25(12):2652-60. PubMed ID: 24012497
    [Abstract] [Full Text] [Related]

  • 3. Long interspersed nucleotide acid element-1 ORF-1 protein promotes proliferation and invasion of human colorectal cancer LoVo cells through enhancing ETS-1 activity.
    Li MY, Zhu M, Feng F, Cai FY, Fan KC, Jiang H, Wang ZQ, Linghu EQ.
    Genet Mol Res; 2014 Apr 14; 13(3):6981-94. PubMed ID: 24782214
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 14; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

  • 5. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 May 14; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 6. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 8. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 9. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-4 in patients with prostate cancer.
    Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T.
    Anticancer Res; 2005 Feb 01; 25(6C):4595-8. PubMed ID: 16334148
    [Abstract] [Full Text] [Related]

  • 11. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.
    Clin Cancer Res; 2013 Oct 15; 19(20):5613-25. PubMed ID: 23995860
    [Abstract] [Full Text] [Related]

  • 12. Hypoxia increases androgen receptor activity in prostate cancer cells.
    Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM.
    Cancer Res; 2006 May 15; 66(10):5121-9. PubMed ID: 16707435
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ.
    Mol Cell Endocrinol; 2004 May 31; 220(1-2):109-23. PubMed ID: 15196705
    [Abstract] [Full Text] [Related]

  • 14. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
    Berrevoets CA, Umar A, Trapman J, Brinkmann AO.
    Biochem J; 2004 May 01; 379(Pt 3):731-8. PubMed ID: 14744261
    [Abstract] [Full Text] [Related]

  • 15. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.
    Slupianek A, Yerrum S, Safadi FF, Monroy MA.
    J Cell Physiol; 2010 Aug 01; 224(2):369-75. PubMed ID: 20432434
    [Abstract] [Full Text] [Related]

  • 16. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD, Lambert JR, Nordeen SK.
    Mol Cancer Res; 2010 Dec 01; 8(12):1643-55. PubMed ID: 21047772
    [Abstract] [Full Text] [Related]

  • 17. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 18. MEIS1 functions as a potential AR negative regulator.
    Cui L, Li M, Feng F, Yang Y, Hang X, Cui J, Gao J.
    Exp Cell Res; 2014 Oct 15; 328(1):58-68. PubMed ID: 25158280
    [Abstract] [Full Text] [Related]

  • 19. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
    Wang LG, Ossowski L, Ferrari AC.
    Oncogene; 2004 Jul 01; 23(30):5175-84. PubMed ID: 15156193
    [Abstract] [Full Text] [Related]

  • 20. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS.
    Cancer Res; 2006 Nov 01; 66(21):10613-20. PubMed ID: 17079486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.